Magnetic Seizure Therapy for Schizophrenia - Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre for Addiction and Mental Health
About this trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
Eligibility criteria
Qualifiers
are inpatients or outpatients;
demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR);
have a DSM-5 diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0);
are 18 years of age or older;
Disqualifiers
have a history of MINI diagnosis of a substance use disorder (other than nicotine and caffeine) within the past three months;
have a concomitant major unstable medical illness;
are pregnant or intend to get pregnant during the study;
have probable dementia based on study investigator assessment;
Trial design
Treatments tested in this trial
- Magnetic Seizure Therapy (MST)
- Electroconvulsive Therapy (ECT)
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Centre for Addiction and Mental Health
Lead sponsor
University of British Columbia
Collaborator
Source ClinicalTrials.gov